Patient Summary

• 45M, Type 2 DM
• Current regimen: Metformin 500 mg 1-0-1 (1 g/day) + Glimepiride 1 mg OD
• Fasting BSL: 201 mg/dL | Postprandial: 325 mg/dL
• Constraint: Cost - must use affordable/generic medications only

Problem Analysis

1. Metformin 500 mg BD = only 1 g/day - therapeutic benefit continues up to 2000 mg/day; max effective dose is ~2000-2500 mg. He is on a sub-therapeutic dose.
2. Glimepiride 1 mg OD - the range is 1-8 mg/day; 1 mg is the starting dose, not the optimized dose.
3. Postprandial of 325 points significantly to prandial (post-meal) glucose not being covered - needs a drug or dose targeting postprandial spikes.

Step 1 - Optimize What He Is Already On (Free Change, No New Cost)

Step 2 - Affordable Add-On / Substitution Options

Option A - Add Pioglitazone 15 mg OD (Best Affordable Add-on)

• Cost: ~INR 2-4/tablet (very cheap)
• Mechanism: Insulin sensitizer (PPAR-gamma agonist) - works differently from both Metformin and Glimepiride, so additive benefit
• HbA1c reduction: ~0.5-1.4%
• Benefit: Reduces both FBS and PPBS; also improves lipids (raises HDL, lowers TG)
• Caution: Causes fluid retention/edema and weight gain (~2-3 kg). Check for cardiac failure or liver disease first. Also associated with bladder cancer risk with long-term use.
• Triple combo: Met + Glimi + Pio = proven effective in Indian studies (PMC11157142)
• Start at: 15 mg OD with food

Option B - Switch Glimepiride to Glipizide (Even Cheaper Sulfonylurea)

• Cost: ~INR 1-2/tablet (Glipizide + Metformin FDC is ~INR 2/tablet)
• Glipizide 5 mg before breakfast; can go up to 20 mg/day in 2 divided doses
• Why consider: Glipizide is shorter-acting, lower risk of prolonged hypoglycemia compared to Glimepiride (especially important if the patient skips meals)
• Equivalence: Glipizide 5 mg ≈ Glimepiride 1-2 mg in effect
• Alternatively: Keep Glimepiride and dose-optimize (simpler)

Option C - Add Voglibose 0.2-0.3 mg TDS (Excellent for High PPBS)

• Cost: ~INR 3-6/tablet
• Mechanism: Alpha-glucosidase inhibitor - delays carbohydrate absorption, specifically blunts postprandial spikes
• Ideal for this patient: His PP of 325 is very high - Voglibose directly targets this
• Take: With first bite of each main meal, TDS
• HbA1c reduction: ~0.5-0.8%
• Side effects: Flatulence, bloating, diarrhea (usually settles after 2-4 weeks)
• No hypoglycemia as monotherapy; no weight gain
• Voglibose is also available as FDC with Metformin

Option D - Repaglinide 0.5-1 mg Before Meals (Prandial Secretagogue)

• Cost: Moderate-cheap (~INR 5-8/tablet)
• Best for: High postprandial glucose; short-acting so taken before meals only
• Note: Avoid combining with Glimepiride (same class/mechanism - both are secretagogues, combining them increases hypoglycemia risk without much added benefit)
• If choosing Repaglinide, consider stopping Glimepiride and using Repaglinide instead

Recommended Practical Regimens (Prioritized by Cost-Effectiveness)

Regimen 1 - Optimize existing drugs first (Zero extra cost)

Metformin 1000 mg BD + Glimepiride 2-4 mg OD

Regimen 2 - Best affordable triple therapy

Metformin 1000 mg BD + Glimepiride 2 mg OD + Pioglitazone 15 mg OD (~INR 5-10/day total; proven in Indian population)

Regimen 3 - If postprandial spikes are dominant concern

Metformin 1000 mg BD + Glimepiride 2 mg OD + Voglibose 0.2 mg TDS (with meals) (~INR 8-12/day total)

Regimen 4 - Glipizide FDC (simplest/cheapest)

Glipizide 5 mg + Metformin 500 mg FDC tablet BD (pre-made combination) (~INR 2-4/day; very cheap, good adherence with single tablet)

What to AVOID in a Cost-Constrained Patient

Quick Monitoring Plan

• Check HbA1c in 3 months after optimization
• Target FBS < 130 mg/dL; PP < 180 mg/dL
• Watch for hypoglycemia signs after increasing Glimepiride dose
• If adding Pioglitazone - check for pedal edema monthly; avoid if cardiac/liver disease
• Check LFT before starting Pioglitazone